Literature DB >> 25354967

The course of anaemia in children and adolescents with Crohn's disease included in a prospective registry.

Stephanie Van Biervliet1, Françoise Smets, Ilse Hofmann, Elisabeth Degreef, Bruno Hauser, Patrick Bontems, Saskia Vande Velde, Wim Arts, Isabelle Paquot, Philippe Alliet, Peter Bossuyt, Edouard Louis, Filip Baert, Olivia Bauraind, Jean-François Rahier, Gigi Veereman.   

Abstract

AIM: The aim of this study is to determine the prevalence and evolution of anaemia in prospectively followed children and adolescents diagnosed with Crohn's disease (CD).
METHODS: The BELCRO registry (inclusion May 2008-April 2010), describing current clinical treatment practice of children diagnosed with CD, provided data on age, height, body mass index (BMI), paediatric Crohn's disease activity index (PCDAI), therapy and haemoglobin (Hb) at diagnosis 12 and 24 months follow-up. Anaemia was defined as Hb < -2 sd, while severe anaemia was defined as Hb < -4 sd. Patients were classified as child ≤13 and adolescent >13 years of age. RESULT: Ninety-six were included, 13 dropped out due to insufficient Hb data (37 females/46 males; median age 13.3 years, range 2.2-17.8 years). At diagnosis, the median Hb sd was -2.66 (-8.4; 1.07) and was correlated with the PCDAI (p = 0.013). At diagnosis, 51/83 (61%) were anaemic and all had active disease. Hb z-score significantly improved (p < 0.0001) but 26/68 (38%) remained anaemic at 12 months and 29/76 (38%) at 24 months of follow-up. The correlation to the PCDAI disappeared. At 24 months, children were more likely to be anaemic. There was no difference in iron dose nor duration of iron supplements between children and adolescents. Iron treatment was more readily given to patients presenting with anaemia. Hb did not differ between patients with (n = 28) or without iron supplements. Half of the patients with persisting anaemia were given iron supplements, of which, only three were given intravenously.
CONCLUSION: Anaemia remains an important extra-intestinal manifestation of CD in children. Physicians, lacking optimal treatment strategies, undertreat their patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25354967     DOI: 10.1007/s00384-014-2042-4

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  14 in total

Review 1.  Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and meta-analysis.

Authors:  Thomas W Lee; Michael R Kolber; Richard N Fedorak; Sander Veldhuyzen van Zanten
Journal:  J Crohns Colitis       Date:  2011-10-26       Impact factor: 9.071

2.  Efficacy and tolerability of oral iron therapy in inflammatory bowel disease: a prospective, comparative trial.

Authors:  A D de Silva; E Tsironi; R M Feakins; D S Rampton
Journal:  Aliment Pharmacol Ther       Date:  2005-12       Impact factor: 8.171

3.  Slow hematological recovery in children with IBD-associated anemia in cases of "expectant management".

Authors:  Lise P M Pels; Els Van de Vijver; Herman J Waalkens; Jan Uitentuis; Gieneke JGonera-de ong; Lidy A T van Overbeek; Obbe F Norbruis; Edmond H H M Rings; Patrick F van Rheenen
Journal:  J Pediatr Gastroenterol Nutr       Date:  2010-12       Impact factor: 2.839

4.  Anaemia and iron deficiency in children with inflammatory bowel disease.

Authors:  Anthony E Wiskin; Ben J Fleming; Stephen A Wootton; R Mark Beattie
Journal:  J Crohns Colitis       Date:  2012-01-17       Impact factor: 9.071

5.  Treatment of iron deficiency anemia in pediatric inflammatory bowel disease.

Authors:  Meena Thayu; Petar Mamula
Journal:  Curr Treat Options Gastroenterol       Date:  2005-10

6.  Assessing activity of pediatric Crohn's disease: which index to use?

Authors:  A Otley; H Loonen; N Parekh; M Corey; P M Sherman; A M Griffiths
Journal:  Gastroenterology       Date:  1999-03       Impact factor: 22.682

7.  Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases.

Authors:  Christoph Gasche; Arnold Berstad; Ragnar Befrits; Christoph Beglinger; Axel Dignass; Kari Erichsen; Fernando Gomollon; Henrik Hjortswang; Ioannis Koutroubakis; Stefanie Kulnigg; Bas Oldenburg; David Rampton; Oliver Schroeder; Jürgen Stein; Simon Travis; Gert Van Assche
Journal:  Inflamm Bowel Dis       Date:  2007-12       Impact factor: 5.325

8.  Oral and intravenous iron treatment in inflammatory bowel disease: hematological response and quality of life improvement.

Authors:  Javier P Gisbert; Fernando Bermejo; Ramón Pajares; Jose-Lázaro Pérez-Calle; María Rodríguez; Alicia Algaba; Noemí Mancenido; Felipe de la Morena; Jose Antonio Carneros; Adrián G McNicholl; Yago González-Lama; José Maté
Journal:  Inflamm Bowel Dis       Date:  2009-10       Impact factor: 5.325

Review 9.  Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature.

Authors:  Alisa Wilson; Eileen Reyes; Josh Ofman
Journal:  Am J Med       Date:  2004-04-05       Impact factor: 4.965

10.  Profile of pediatric Crohn's disease in Belgium.

Authors:  E De Greef; J M Mahachie John; I Hoffman; F Smets; S Van Biervliet; M Scaillon; B Hauser; I Paquot; P Alliet; W Arts; O Dewit; H Peeters; F Baert; G D'Haens; J F Rahier; I Etienne; O Bauraind; A Van Gossum; S Vermeire; F Fontaine; V Muls; E Louis; F Van de Mierop; J C Coche; K Van Steen; G Veereman
Journal:  J Crohns Colitis       Date:  2013-05-09       Impact factor: 9.071

View more
  1 in total

1.  Anemia Screening, Prevalence, and Treatment in Pediatric Inflammatory Bowel Disease in the United States, 2010-2014.

Authors:  Steven D Miller; Carmelo Cuffari; Eboselume Akhuemonkhan; Anthony L Guerrerio; Harold Lehmann; Susan Hutfless
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2019-02-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.